


SUMMARY OF EXTRAMURAL SUPPORT

The record of extramural support is an especially noteworthy accomplishment of faculty actively engaged in research in the College of Medicine. The principal investigator is listed on the summary report, but many projects involve other faculty as co-investigators on grants, a practice highly encouraged by the administration. Funding for the 2000-2001 academic year includes \$18,581,025 and \$2,142,163 administered through the University's Office of Sponsored Programs and the South Alabama Medical Science Foundation, respectively.

EXTRAMURAL FUNDS Totals for Recent Years

1990	\$ 10,658,000
1991	13,275,000
1992	11,563,000
1993	11,223,000
1994	11,859,000
1995	14,272,462
1996	16,507,457
1997	14,891,699
1998	18,338,972
1999	19,108,225
2000	20,431,119
2001	20,723,188

College of Medicine Total Annual Extramural Funds From All Sources



COMPREHENSIVE SICKLE CELL CENTER

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Johnson Haynes, Jr.	Comprehensive Sickle Cell Center Program*	NIH	\$1,212,967
			<u>\$1,212,967*</u>

* The individual projects are listed in Departmental Sections.

154

DEAN'S OFFICE

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Samuel J. Strada	Cardiovascular Research for Medical Students	SE Affiliate AHA	\$ 10,800
			<u>\$ 10,800</u>

EMERGENCY MEDICINE

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Frank Pettyjohn	A Randomized, Double-Blind, Double-Dummy, Multicenter, Parallel Group Study to Assess the Effectiveness and Health Economic Impact of Oral Factive, 320mg Once Daily for 5 Days Versus Oral Clarithromycin 500mg Twice Daily for 7 Days for the Treatment of Acute Exacerbation of Chronic Bronchitis	SmithKline Beecham	\$ 9,988
	A Randomized, Double-Blinded, Placebo-Controlled, Multicenter, Long-Term Efficacy Study Trial of Preventing Hypertension Using Candesartan Cilexetil 16mg in Patients With Borderline Hypertension High Normal Blood Pressure	Astra/IBAH	27,350
	A Double-Blinded, Randomized, Placebo-Controlled, Parallel-Group, Multi-Center, Flexible Dose Study to Evaluate the Efficacy and Safety of Viagra in Males With Erectile Dysfunction and Arterial Hypertension Who Are Taking Multiple Antihypertensive Treatment	Pfizer Inc	15,230
	Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril (OCTAVE), CV137-120	Bristol-Myers Squibb	34,781
	Prospective, Randomized, Double-Blind Study Comparing Faropenem Daloxate 300mg PO BID for 10 Days	Bayer	7,191
	Prospective, Randomized, Double-Blind, Multi-Center, Comparative Trial to Evaluate the Efficacy and Safety of Faropenem Daloxate 300mg PO BID for 7 Days vs. Cephalexin 500mg PO BID for 7 Days in the Treatment of Uncomplicated Skin and Structure Infections	Bayer	8,956

EMERGENCY MEDICINE (CONT)

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Frank Pettyjohn	A 6-Week, Open-Label, Dose Comparison Study to Evaluate the Safety and Efficacy of Rosuvastatin Versus Atorvastatin, Cerivastatin, Pravastatin, and Simvastatin in Subjects With Hypercholesterolemia	AstraZeneca	\$ 5,000
	A Randomized, Double-Blind, Placebo-Controlled, Forced Titration Study of Ascending Doses of CS-866, Losartan and Valsartan in Patients With Essential Hypertension	Sankyo	4,605
	AMAZE: Antihypertensive Efficacy of Adding Candesartan Cilexetil to Lisinopril in Comparison to Up-titration of Lisinopril. A Multi-center Trial Using ATACAND-ZESTRIL vs ZESTRIL to Evaluate the Effects on Lowering Blood Pressure – the AMAZE Program	AstraZeneca	4,400
Botros Rizk	Multicenter Efficacy Study Comparing EMD 90 171, a Once a Week Estradiol-Levonorgestrel Combination Transdermal System, With Placebo in the Treatment of Vasomotor Symptoms Associated With Menopause**	Solvay	81,254
	Teriparatide Compared With Alendronate on Spine Bone Mineral Density in Postmenopausal Women With Osteoporosis**	Eli Lilly & Co	6,026
			<u>\$ 204,781</u>

**Not added to this total.

FAMILY PRACTICE AND COMMUNITY MEDICINE

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Mary K. Barfield	NHSC Search Program	HRSA (ADPH)	\$ 10,000
	Student Preceptorship Subsidy	AFP, RHB	50,000
R. Allen Perkins	A Competency Based Third Year Family Medicine Curriculum (Residency Training Grant)	HRSA (BHPR)	140,400
	Academic Faculty/Rural Physician Reciprocal Mini-Residency Program	ADPH (RHB)	33,000
			<u>\$ 233,400</u>

LUNG BIOLOGY PROGRAM/LUNG INSTITUTE

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Troy Stevens	Lung Endothelial Cell Phenotypes+	NIH	\$1,316,540
			<u>\$1,316,540+</u>

+ The individual projects are listed in Departmental Sections.

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Wladimir Wertelecki	Children's Rehabilitation Services Genetics Grant "Southwest Alabama Integrated Health Services for Genetic Disorders"	HRSA (Subcon ADRS)	\$ 173,800
	South Alabama Regional Genetics Program	HRSA (ADPH)	50,000
	Genetics and Mental Health Program	AMHM	137,268
	Alabama Birth Defects Surveillance & Prevention Program (Supplement)	CDC	141,044
	Ukranian Birth Defects Project	USAID	1,000,000
	Nutrition, Dietary Control and Phenylketonuria	USAID	8,000
			<u>\$ 1,510,112</u>

INTERNAL MEDICINE

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Michael V. Cohen	Catechols and Adenosine in Myocardial Preconditioning	NIH	\$ 203,616
Marcel E. Conrad	Regulators of Iron Absorption	NIH	385,665
	Minority-Based Clinical Oncology Program	NIH	284,788
	The Star Trial – Master Purchased Services Agreement	NSABP Fdn	6,000
Michael Culpepper	A Study Evaluating the Initiation and Titration of Fixed Doses of Novel Erythropoiesis Stimulating Protein Therapy in Subject With Chronic Renal Insufficiency	Amgen	9,619
	Randomized, Double-Blind, Comparator Controlled Trial to Evaluate the Pharmacodynamic Effects, Pharmacokinetics and Safety of M100240 in Subject With Essential Hypertension Treated for 4 Weeks	Aventis	51,558
Jack DiPalma	Comparison of the Clinical Safety and Efficacy of Pantoprazole 10mg, 20mg, or 40mg Once Daily and Placebo in Patients With Symptomatic Erosive Esophagitis	Wyeth-Ayers Res	7,839
	Braintree-Colon Cleansing Comparison	Braintree Labs	36,081
T. Michael Fan	Apoptosis and Ischemic Preconditioning	Am Heart Assn SE Affiliate	30,000

INTERNAL MEDICINE (CONT)

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
T. Michael Fan	Suppression of Myocyte Apoptosis by Ischemic/Hypoxic Preconditioning - Role of BCI-2 Phosphorylation	Am Heart Assn	\$ 65,000
Joe Hardin	A Multicenter, Randomized Double-Blind Placebo-Controlled Phase III Study of the Human Anti-TNF Monoclonal Antibody D1E7 Administered as Subcutaneous Injections to Patients With Active Rheumatoid Arthritis Currently Receiving Treatment With Methotrexate	Knoll/BASF	21,280
Johnson Haynes	Acute Lung Injury in Sickle Cell Disease*	NIH	107,369
	Education of Health Professionals*	NIH	95,960
	Comprehensive Sickle Cell Administrative Core*	NIH	371,218
Jorge Herrera	Chronic Hepatitis Research	Integrated Therapeutics	28,120
	Efficacy of 15 mcg INFERGEN for Chronic Hepatitis C in Patients Who Are Non-Responders and Relapsers	Amgen	5,280
	High Dose Interferon +Ribavarin Therapy for Patients With Chronic Hepatitis C Who Failed Prior Treatment	Schering Corp	5,250
	A Prospective, Randomized, Multi-Center, Open-Label Comparative Safety Study of Pagasys vs Pegasys Plus Ribavarin Treatment vs. A 12-Week Treatment Delay in Patients With Chronic Hepatis C	Roche Labs	5,097

INTERNAL MEDICINE (CONT)

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Candace C. McCombs	Grants Program Management	Sequeila Global Tuberculosis Fdn	\$ 72,036
Jack Painter	An Open Study, With Blinded Endpoint Assessment, to Assess the Safety, Tolerability, and the Effect on Coronary Artery Patency of Intravenous AR-C69931MX as Both Monotherapy and Adjunct to Activase in Patients With St-Elevation Myocardial Infarction	Astra/Henry Ford	14,250
	A Randomized, Double-Blind, Placebo-Controlled Study of Two Intravenous Dosing Regimens of h5G1,1-scFv in Patients With Acute Myocardial Infarction Undergoing Thrombolytic Reperfusion Therapy	Proctor & Gamble	10,125
Jay Umbreit	Inhibition of Intestinal HEME Iron Absorption	NIH	33,000
			<hr/>
			\$1,849,151

MICROBIOLOGY/IMMUNOLOGY

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Joseph H. Coggin	Use of ILRP and OFA as Vaccine in Rodent Tumor Therapy	NIH	\$ 264,843
	OFA Technology Research	Biomira	18,500
John W. Foster	Mechanisms in Control of Acid Resistance in E. Coli	NIH	239,439
	Novel Molecular Approaches to Eradicate E. Coli 0157 From the Bovine GI Tract	USDA	74,002
Robert N. Lausch	Role of MIP-2 in HSV-1 Induced Corneal Inflammation	NIH	248,969
John E. Oakes	Chemokine Gene Regulation in Human Corneal Epithelia	NIH	274,235
Herbert H. Winkler	Permeability of the Epidemic Typhus Rickettsia	NIH	544,014
	Genomic Level Expression Patterns in Typhus Rickettsiae	NIH	277,875
David O. Wood	Genetic Analysis of Rickettsia Prowazekii	NIH	321,035
	Transport of S-Adenosylmethionine in Rickettsia	NIH	264,680
			<u>\$ 2,527,592</u>

NEUROLOGY

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Jane Boggs	Open-Label, Safety Study of Gabapentin as Adjunct Therapy in Children Aged 1 Month Through 4 Years With Seizures Uncontrolled by Current Anticonvulsant Drugs	Parke-Davis (Warner Lambert)	\$ 9,600
Jorge Mendizabal	A Multicenter, Double-Blind, Randomized, Parallel Group Study of the Safety and Efficacy of BOTOX Purified Neurotoxin Complex for the Prophylactic Treatment of Migraine Headache	Allergan	7,750
	A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of BOTOX Purified Neurotoxin Complex for the Prophylactic Treatment of Migraine Headaches	Allergan	13,470
John Rothrock	Patient Preference for Migraine Headache Therapy: Imitrex Tablets Versus Current (Non-Triptan) Therapy	GlaxoWellcome	5,400
Richard M Zweifler	Siblings With Ischemic Stroke Study (SWISS)	NIH – Subcon Mayo Fdn	5,000
	Vitamin Intervention for Stroke Prevention	NIH -- Subcon Bowman-Gray	55,471
	Warfarin VS Aspirin for Intracranial Arterial Stenosis (WSAID)	NIH -- Subcon Emory	40,192
	A Double-Blind, Placebo-Controlled, Safety, Efficacy, and Dose Response Trial of Three Intravenous Dosages of BMS 204352 in Patients With Acute Stroke	Bristol Myers Squibb	10,080

ORTHOPAEDIC SURGERY

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Viorel Raducan	Biomechanical Properties of C1-C2 Interlaminar Claw Fixation for Treatment of C1-C2 Instability	Medtronic, Inc.	14,000
			<u>\$ 14,000</u>

PATHOLOGY

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Miguel Pappolla	A Pilot Trial of Long-Term Melatonin in AD	Alzheimer's Assn.	\$ 125,000
	Melatonin as a New Anti-Amyloidogenic and Antioxidant Agent	NIH	290,094
	Mindset Limited Research Agreement	Mindset Limited	80,000
William Gardner	INDYNE Cooperative Service	Indyne/Information Dynamics	5,308
			<u>\$ 500,402</u>

PEDIATRICS

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Benjamin Estrada	Linezolid IV/PO vs Vancomycin IV for the Treatment of Resistant Gram-Positive Bacterial Infections in Children	Pharmacia & Upjohn	\$ 8,805
David Gremse	A Randomized, Double-Blind, Parallel, Multicenter Pediatric Study of Axid (Nizatidine) Versus Placebo in the Treatment of Gastroesophageal Reflux Disease (GERD) in Children Age 1-12	Reliant Pharm, LLC	10,420
	A Multicenter, Randomized, Single-Blind Study to Evaluate Omeprazole for the Treatment of Clinically Diagnosed GERD in Pediatric Patients Ages 0 Months Through 24 Months, Inclusive	AstraZeneca/ Covance	28,308
	A Multicenter, Open Label Study of the Efficacy and Safety of Exisulind at the Highest Tolerated Dose in Pediatric With Intact Colons and a Diagnosis of Adenomatous Polyposis Coli	Cell Pathways	34,675
Mary Y. Mancao	Southeast Pediatric Aids Clinical Trial Unit	NIH (Subcon UAB)	325,761
	USA Family Specialty Clinic	HRSA	251,475
Betty Pace	A Study to Assess the Safety, Dose Conversion and Titration of Duragesic in Pediatric Patients With Chronic Pain Requiring Opioid Therapy	Janssen/Quintiles Pacific	12,925

PEDIATRICS (CONT)

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Jorge Quinonez	Linezolid vs Cefadroxil in the Treatment of Skin and Skin Structure Infections in Children	Pharmacia & Upjohn	\$ 26,375
Kenneth Rettig	An Open Label Trial Evaluating the Safety and Efficacy of Nolvadex in the Treatment of McCune-Albright Syndrome	AstraZeneca Pharm	7,000
Lawrence J. Sindel	Cystic Fibrosis Center Program	Cystic Fibrosis Fdn	23,797
Franklin Trimm	Neonatal Follow-Up Project	ADPH	50,380
	Development of Center of Excellence	Ala Dept Rehab Svcs	11,069
			<u>\$ 790,990</u>

PHARMACOLOGY

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
June Ayling	Accumulation of Folic Acid Polyglutamates: A Potential Cause of Inadequate Response to Treatment of Hyperhomocysteinemia	SE Affiliate AHA	\$ 60,000
	Alabama Structural Biology Consortium	NSF (Sub U/AL/Huntsville)	150,000
	Crystallography of Dehydratase/DCoH: A Target of Lung Disease	NASA	30,000
	Vitamin Project	Merck	74,711
Michael D. Chinkers	Glucocorticoid Receptor Regulation by Protein Phosphatase 5	NIH	205,233
Mark N. Gillespie	DNA Lesions and Gene Expression in Hypoxic Lung Disease	NIH	265,857
	Mitochondrial DNA Integrity and Endothelial Cell Free Radical Stress+	NIH	292,598
Jack Olson	Pulmonary Endothelial Cell Wound Repair and Polyamines	AHA SE Affiliate	60,000
	Lung Endothelial Cell Phenotypes Core 3: Gene Delivery+	NIH	158,631
Jonathan C. Scammell	An Animal Model of Glucocorticoid Resistance	NIH	208,610
	Experimental Infection of Squirrel Monkey B-Lymphocytic Cell Lines With Creutzfeldt-Jacob Disease	Baxter	91,555

PHYSIOLOGY (CONT)

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Aubrey E. Taylor	T-Lymphocyte Involvement in Lung Ischemia-Reperfusion Injury	NIH	\$ 289,000
Mary I. Townsley	Regulation of Pulmonary Endothelial Permeability	NIH	234,495
			<u>\$2,302,315</u>

RADIOLOGY

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Greg Cotter	A Phase III, Randomized, Open-Label, Comparative Study of Standard Whole Brain Radiation Therapy With or Without RSR13 in Patients With Brain Metastases	Allos Therapeutics, Inc.	\$ 7,694
			<u>\$ 7,694</u>

RURAL HEALTH

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Regina M. Benjamin	Application for Basic/Core AHEC Grant	HRSA (BHPR)	\$1,334,226
	CME Video Library	Ernest Debakey Charitable Fdn	8,782
	USA Telemedicine	HRSA	864,000
C. Taylor	A Feasibility Study for Telemedicine	HRSA	115,000
			<u>\$2,322,008</u>

SURGERY

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEARS TOTAL FUNDING</u>
Richard P. Gonzalez	A Prospective, Randomized, Double-Blind, Multi-Center Trial Assessing the Safety and Efficacy of Sequential Bay 12-8039 (Moxifloxacin) 400 mg Every 24 Hours Compared to Intravenous Piperacillin/Tazofactam 3.375gm Every 6 Hours Followed by Oral Amoxicillin/Clavulanic Acid Suspension 800mg Every 12 Hours for the Treatment of Patients With Complicated Intra-Abdominal Infections	Bayer	\$ 10,180
	Center to Study Rural Vehicular Trauma	DOT	500,000
Arnold Luterman	Clinical Evaluation of Regranex (becaplermin) Gel 0.01% for the Treatment of Full Thickness Diabetic Neuropathic Foot Ulcers	Ortho-McNeil	7,500
	A Phase II Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Parallel Group, Multi-Center Study of the Effects of PB00d on the Re-Epithelialization of Donor Sites in Patients With Burns Which Require Skin Grafting	Pharmadigm	20,887
	INTEGRA Artificial Skin - Post Approval Study	Integra LifeSci Corp	21,600
	A Prospective, Randomized, Double-Blind, Multi-Center Trial Assessing the Safety and Efficacy of Sequential BAY 12-8039 (Moxifloxacin) 400 mg Every 24 Hours Compared to Intravenous Piperacillin/Tazofactam 3.0/0.375g Every 6 Hours Followed by Oral Amoxicillin/Clavulanic Acid Suspension 800gm Every 12 Hours for the Treatment of Patients With Complicated Skin and Skin Structure Infections	Bayer Corp	7,938

SURGERY (CONT)

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEARS TOTAL FUNDING</u>
Arnold Luterman	A Randomized, Controlled, Within-Patient-Paired Study to Compare the Effectiveness of TranCyte and Biobrane In the Treatment of Mid-Dermal to Indeterminate Depth Burn Wounds	Advanced Tissue Sci	\$ 16,813
Jeffrey D. Manord	A Randomized, Double-Blinded, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Repifermin (KGF2) in Subjects With Venous Ulcers	Human Genome Science	19,186
			<hr/> \$ 604,104

PEDIATRICS (CONT)

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Jorge Quinonez	Linezolid vs Cefadroxil in the Treatment of Skin and Skin Structure Infections in Children	Pharmacia & Upjohn	\$ 26,375
Kenneth Rettig	An Open Label Trial Evaluating the Safety and Efficacy of Nolvadex in the Treatment of McCune-Albright Syndrome	AstraZeneca Pharm	7,000
Lawrence J. Sindel	Cystic Fibrosis Center Program	Cystic Fibrosis Fdn	23,797
Franklin Trimm	Neonatal Follow-Up Project	ADPH	50,380
	Development of Center of Excellence	Ala Dept Rehab Svcs	11,069
			<u>\$ 790,990</u>

PHARMACOLOGY

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
June Ayling	Accumulation of Folic Acid Polyglutamates: A Potential Cause of Inadequate Response to Treatment of Hyperhomocysteinemia	SE Affiliate AHA	\$ 60,000
	Alabama Structural Biology Consortium	NSF (Sub U/AL/Huntsville)	150,000
	Crystallography of Dehydratase/DCoH: A Target of Lung Disease	NASA	30,000
	Vitamin Project	Merck	74,711
Michael D. Chinkers	Glucocorticoid Receptor Regulation by Protein Phosphatase 5	NIH	205,233
Mark N. Gillespie	DNA Lesions and Gene Expression in Hypoxic Lung Disease	NIH	265,857
	Mitochondrial DNA Integrity and Endothelial Cell Free Radical Stress+	NIH	292,598
Jack Olson	Pulmonary Endothelial Cell Wound Repair and Polyamines	AHA SE Affiliate	60,000
	Lung Endothelial Cell Phenotypes Core 3: Gene Delivery+	NIH	158,631
Jonathan C. Scammell	An Animal Model of Glucocorticoid Resistance	NIH	208,610
	Experimental Infection of Squirrel Monkey B-Lymphocytic Cell Lines With Creutzfeldt-Jacob Disease	Baxter	91,555

PHARMACOLOGY (CONT)

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Stephen Schaffer	Effect of Diabetes and Hypertension on Ischemic Injury	NIH	\$ 248,405
Troy Stevens	Glucose-Induced Protection Against Hypoxia-Induced Apoptosis	Am Heart Assn SE Affiliate	35,000
	Regulation of Pulmonary Resistance Vessels	NIH (Subcon Wakeforest)	26,046
	Store Operated CA2+ Entry: Lung Endothelial Permeability	NIH	239,111
	Lung Endothelial Cell Phenotypes Core 1: Administrative+	NIH	129,963
	Lung Endothelial Cell Phenotypes Core 2: Cell Culture+	NIH	187,947
	Calcium Inhibition of cAMP in Endothelial Cell Permeability+	NIH	279,138
W. Joseph Thompson/ S.J. Strada	Cell Pathways Collaborative Research	Cell Pathways	28,734
	Endothelial Cell cGMP Receptors and Function	NIH	275,708
Danna Zimmer	Studies of Interactions Between P53 and S100 Proteins	ACS – Subcon Univ MD	31,530
	Mechanisms for Fetal Hemoglobin Induction*	NIH	100,661
	Deciphering the Cellular Functions of Aldolase	NIH – Subcon Boston Univ	18,000
			<u>\$3,197,438</u>

PHYSIOLOGY

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Stephen T. Ballard	Airway Submucosal Glands and Cystic Fibrosis Disease	NIH	\$ 294,138
Joseph N. Benoit	Pharmacological Model of Cystic Fibrosis Lung Disease	Cystic Fibrosis Fdn	43,200
	Intestine in Chronic Portal Hypertension	NIH	260,100
	Role Collecting Lymphatic Pumps in Prevention of Interstitial Edema	Lymphedema Fdn	6,250
Michael V. Cohen	Catechols and Adenosine in Myocardial Preconditioning**	NIH	203,616
James M. Downey	Physical Factors and Coronary Flow	NIH	187,616
	KAPPA-PVIIA a KATP Opener With Anti-Ischemic Potential	NIH (Subcon Cognetix)	24,000
	AMP 579 Research	Aventis	50,000
	Rabbit Myocardial Infarction Research	Maxim	36,250
James C. Parker	Mechanogated Calcium Entry in Pulmonary Injury	NIH	240,237
	Airway Perfusion Assisted Liquid Ventilator	STTR Phase II	149,951
	Mechanical Injury to Lung Endothelium+	NIH	283,462

171

** Not added in total.

PHYSIOLOGY (CONT)

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Aubrey E. Taylor	T-Lymphocyte Involvement in Lung Ischemia- Reperfusion Injury	NIH	\$ 289,000
Mary I. Townsley	Regulation of Pulmonary Endothelial Permeability	NIH	234,495
			<u>\$2,302,315</u>

RADIOLOGY

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEARS TOTAL FUNDING</u>
Greg Cotter	A Phase III, Randomized, Open-Label, Comparative Study of Standard Whole Brain Radiation Therapy With or Without RSR13 in Patients With Brain Metastases	Allos Therapeutics, Inc.	\$ 7,694
			<u>\$ 7,694</u>

RURAL HEALTH

<u>PRINCIPAL INVESTIGATOR</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEARS TOTAL FUNDING</u>
Regina M. Benjamin	Application for Basic/Core AHEC Grant	HRSA (BHPR)	\$1,334,226
	CME Video Library	Ernest Debakey Charitable Fdn	8,782
	USA Telemedicine	HRSA	864,000
C. Taylor	A Feasibility Study for Telemedicine	HRSA	115,000
			<u>\$2,322,008</u>

SURGERY

YEARS TOTAL FUNDING

PRINCIPAL INVESTIGATOR

PROJECT TITLE

AGENCY

\$ 10,180

Richard P. Gonzalez

A Prospective, Randomized, Double-Blind, Multi-Center Trial Assessing the Safety and Efficacy of Sequential Bay 12-8039 (Moxifloxacin) 400 mg Every 24 Hours Compared to Intravenous Piperacillin/Tazofactam 3.375gm Every 6 Hours Followed by Oral Amoxicillin/Clavulanic Acid Suspension 800mg Every 12 Hours for the Treatment of Patients With Complicated Intra-Abdominal Infections

Bayer

Center to Study Rural Vehicular Trauma

DOT

500,000

Arnold Luterman

Clinical Evaluation of Regranex (becaplermin) Gel 0.01% for the Treatment of Full Thickness Diabetic Neuropathic Foot Ulcers

Ortho-McNeil

7,500

A Phase II Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Parallel Group, Multi-Center Study of the Effects of PB00d on the Re-Epithelialization of Donor Sites in Patients With Burns Which Require Skin Grafting

Pharmadigm

20,887

INTEGRA Artificial Skin - Post Approval Study

Integra LifeSci Corp

21,600

A Prospective, Randomized, Double-Blind, Multi-Center Trial Assessing the Safety and Efficacy of Sequential BAY 12-8039 (Moxifloxacin) 400 mg Every 24 Hours Compared to Intravenous Piperacillin/Tazofactam 3.0/0.375g Every 6 Hours Followed by Oral Amoxicillin/Clavulanic Acid Suspension 800gm Every 12 Hours for the Treatment of Patients With Complicated Skin and Skin Structure Infections

Bayer Corp

7,938

<u>PRINCIPAL INVESTIGATOR</u>	<u>SURGERY (CONT)</u>	<u>PROJECT TITLE</u>	<u>AGENCY</u>	<u>YEAR'S TOTAL FUNDING</u>
Arnold Luterman		A Randomized, Controlled, Within-Patient-Paired Study to Compare the Effectiveness of TranCyte and Biobrane In the Treatment of Mid-Dermal to Indeterminate Depth Burn Wounds	Advanced Tissue Sci	\$ 16,813
Jeffrey D. Manord		A Randomized, Double-Blinded, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Repifermin (KGF2) in Subjects With Venous Ulcers	Human Genome Science	19,186
				<u>\$ 604,104</u>

**RANKING OF UNITED STATES MEDICAL SCHOOLS
ACCORDING TO FUNDS AWARDED BY
NATIONAL INSTITUTES OF HEALTH
DURING FISCAL YEAR 2000**

The College of Medicine's rank among all U.S. medical schools for fiscal year 2000 was 96th. Please note that this ranking is for National Institutes of Health funds only, and does not include extramural funding from other granting agencies. Please also note that the information presented here is for FY 2000, because of the delay in receipt of NIH reports.

<u>RANK</u>	<u>INSTITUTION</u>	<u>TOTAL NIH FUNDS</u>
80	University of South Florida Col of Med	\$ 18,325,557
81	St Louis University Sch of Medicine	17,447,569
82	SUNY Buffalo Sch of Medicine	16,951,582
83	Morehouse College School of Medicine	16,126,962
84	Tulane University Sch of Medicine	16,105,301
85	New York Medical College	15,902,626
86	University of Puerto Rico Sch of Med	13,838,110
87	Med Coll of Pennsylvania/Hahnemann Univ Sch of Med	13,593,446
88	George Washington Univ Sch of Medicine	12,943,626
89	Howard University College of Medicine	12,718,924
90	University of Louisville Sch of Medicine	12,689,272
91	Univ of Mississippi Sch of Medicine	12,044,807
92	Univ of Missouri Columbia Sch of Med	11,649,085
93	Texas A&M Univ Col of Medicine	11,161,404
94	University of Nevada Sch of Medicine	11,007,562
95	SUNY Hlth Scis Ctr Syracuse Col of Med	10,917,952
96	University of South Alabama Sch of Med	10,734,626
97	Meharry Medical College Sch of Medicine	8,729,446
98	Charles R. Drew University of Med & Sci	8,614,268
99	Albany Medical College of Union Univ	7,825,455
100	West Virginia University Sch of Medicine	7,760,034
101	Medical College of Ohio at Toledo	7,711,780
102	Michigan State U Col of Human Medicine	5,871,016
103	Wright State University Sch of Medicine	5,320,370
104	Loma Linda University Sch of Medicine	5,200,257
105	Finch Univ of Hlth Scis Chicago Med Sch	5,097,934

<u>RANK</u>	<u>INSTITUTION</u>	<u>TOTAL NIH FUNDS</u>
106	Eastern Virginia Med/Sch Med Col Hamp Rd	\$ 4,944,127
107	Texas Tech Univ Hlth Scis Ctr Sch of Med	4,210,460
108	Univ of Missouri Kansas City Sch of Med	3,812,567
109	Creighton University School of Medicine	3,781,030
110	East Carolina University Sch of Med	3,665,462
111	Univ of South Dakota Sch of Medicine	2,897,498
112	Southern Illinois Univ Sp Sch of Med	2,888,197
113	Univ of North Dakota Sch of Medicine	2,848,833
114	Univ of Hawaii John A Burns Sch of Med	2,497,296
115	Central U of the Caribe Sch Med of Cayey	2,429,176
116	East Tenn St Univ Quillen Med Col	2,361,131
117	Ponce School of Medicine	2,344,734
118	Univ of South Carolina Sch of Medicine	2,252,046
119	Northeastern Ohio Univs College of Med	1,370,257
120	Marshall University School of Medicine	1,013,316
121	Mercer University School of Medicine	871,824